BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1679045)

  • 21. Inhibition of growth of a prolactin and growth hormone-secreting pituitary tumor in rats by D-tryptophan-6 analog of luteinizing hormone-releasing hormone.
    Torres-Aleman I; Redding TW; Schally AV
    Proc Natl Acad Sci U S A; 1985 Feb; 82(4):1252-6. PubMed ID: 2858096
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Growth inhibition of MXT mammary carcinoma by enhancing programmed cell death (apoptosis) with analogs of LH-RH and somatostatin.
    Szende B; Lapis K; Redding TW; Srkalovic G; Schally AV
    Breast Cancer Res Treat; 1989 Dec; 14(3):307-14. PubMed ID: 2575407
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs.
    Szepesházi K; Halmos G; Schally AV; Arencibia JM; Groot K; Vadillo-Buenfil M; Rodriguez-Martin E
    J Cancer Res Clin Oncol; 1999; 125(8-9):444-52. PubMed ID: 10480336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Growth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75.
    Szende B; Srkalovic G; Groot K; Lapis K; Schally AV
    J Natl Cancer Inst; 1990 Mar; 82(6):513-7. PubMed ID: 2156080
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of receptors for somatostatin in various tumors using different analogs.
    Srkalovic G; Cai RZ; Schally AV
    J Clin Endocrinol Metab; 1990 Mar; 70(3):661-9. PubMed ID: 1968467
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of growth of OV-1063 human epithelial ovarian cancer xenografts in nude mice by treatment with luteinizing hormone-releasing hormone antagonist SB-75.
    Yano T; Pinski J; Halmos G; Szepeshazi K; Groot K; Schally AV
    Proc Natl Acad Sci U S A; 1994 Jul; 91(15):7090-4. PubMed ID: 7518926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of growth of a prolactin-secreting pituitary tumor in rats by analogs of luteinizing hormone-releasing hormone and somatostatin.
    de Quijada MG; Redding TW; Coy DH; Torres-Aleman I; Schally AV
    Proc Natl Acad Sci U S A; 1983 Jun; 80(11):3485-8. PubMed ID: 6134284
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumors.
    Lee MT; Liebow C; Kamer AR; Schally AV
    Proc Natl Acad Sci U S A; 1991 Mar; 88(5):1656-60. PubMed ID: 1672042
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of pituitary-gonadal function in male and female rats after prolonged administration of a potent antagonist of luteinizing hormone-releasing hormone (SB-75).
    Bokser L; Srkalovic G; Szepeshazi K; Schally AV
    Neuroendocrinology; 1991 Aug; 54(2):136-45. PubMed ID: 1662786
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antagonists of bombesin/gastrin-releasing peptides as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Pinski J; Halmos G; Szepeshazi K; Schally AV
    Cancer; 1993 Dec; 72(11):3263-70. PubMed ID: 8242552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
    Sharoni Y; Bosin E; Miinster A; Levy J; Schally AV
    Proc Natl Acad Sci U S A; 1989 Mar; 86(5):1648-51. PubMed ID: 2646641
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The concentration of LH-RH receptors in the nuclei of pancreatic cancer cells. Effect of (D-Trp6)LH-RH on tumor-bearing Syrian golden hamsters.
    Szende B; Csikós A; Szepeshazi K; Neill JD; Mulchahey JJ; Halmos G; Lapis K; Schally AV
    Receptor; 1994; 4(4):201-7. PubMed ID: 7894336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Receptors for D-Trp6-luteinizing hormone-releasing hormone, somatostatin, and insulin-like growth factor I in MXT mouse mammary carcinoma.
    Srkalovic G; Szende B; Redding TW; Groot K; Schally AV
    Proc Soc Exp Biol Med; 1989 Dec; 192(3):209-18. PubMed ID: 2574866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Receptors for prolactin, somatostatin, and luteinizing hormone-releasing hormone in experimental prostate cancer after treatment with analogs of luteinizing hormone-releasing hormone and somatostatin.
    Kadar T; Redding TW; Ben-David M; Schally AV
    Proc Natl Acad Sci U S A; 1988 Feb; 85(3):890-4. PubMed ID: 2893378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of bombesin, gastrin-releasing peptide (GRP)(14-27) and bombesin/GRP receptor antagonist RC-3095 on growth of nitrosamine-induced pancreatic cancers in hamsters.
    Szepeshazi K; Schally AV; Groot K; Halmos G
    Int J Cancer; 1993 May; 54(2):282-9. PubMed ID: 8387464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective effects of analogs of luteinizing hormone-releasing hormone against chemotherapy-induced testicular damage in rats.
    Karashima T; Zalatnai A; Schally AV
    Proc Natl Acad Sci U S A; 1988 Apr; 85(7):2329-33. PubMed ID: 2965391
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone.
    Yano T; Pinski J; Radulovic S; Schally AV
    Proc Natl Acad Sci U S A; 1994 Mar; 91(5):1701-5. PubMed ID: 8127868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.
    Reissmann T; Hilgard P; Harleman JH; Engel J; Comaru-Schally AM; Schally AV
    J Cancer Res Clin Oncol; 1992; 118(1):44-9. PubMed ID: 1530849
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of streptozotocin-induced islet cell tumors and N-nitrosobis(2-oxopropyl)amine-induced pancreatic exocrine tumors in Syrian hamsters by exogenous insulin.
    Pour PM; Kazakoff K; Carlson K
    Cancer Res; 1990 Mar; 50(5):1634-9. PubMed ID: 2154330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.